Martin Pfister

Martin Pfister is the current principal and authorized signatory for Life Sciences & Chemistry at High-Tech Gründerfonds. Martin has also served on the advisory board for Cardior Pharmaceuticals, GeneQuine Biotherapeutics, lino Biotech AG, and JeNaCell GmbH. From 2016 to 2020, they were a member of the advisory board for Biametrics GmbH. Before their current position, Pfister was the managing director for biosaxony from 2007 to 2010. Martin also founded dii - an Economist Intelligence Unit - Healthcare business in 2004 and served as a partner until 2018 when they had an exit to The Economist.

Martin Pfister is a medical doctor who has also earned a PhD in immunology. Martin has also studied biopharmacology at Universität Greifswald. In addition to their medical training, they are also certified as a yoga teacher.

Martin Pfister reports to Alex von Frankenberg, Managing Director. Some of their coworkers include Romy Schnelle - Partner, Digital Tech, Frank Kerim Reinecke - Principal & Authorized Signatory, Berlin, and Tobias Schulz - Senior Investment Manager, Digital Tech.